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Abstract
Background: Portugal has a strong tradition of conventional western healthcare. So it provides a natural case study 
for the relationship between Complementary/Alternative Medicine (CAM) and Western Medicine (WM). This work 
aims to test the relationship between CAM and WM users in the diagnosis and treatment stages and to estimate the 
determinants of CAM choice. 
Methods: The forth Portuguese National Health Survey is employed to estimate two single probit models and obtain 
the correlation between the consumption of CAM and WM medicines in the diagnosis and treatment stages. 
Results: Firstly, both in the diagnosis and the treatment stage, CAM and WM are seen to be complementary choices 
for individuals. Secondly, self-medication also shows complementarity with the choice of CAM treatment. Thirdly, 
education has a non-linear relationship with the choice of CAM. Finally, working status, age, smoking and chronic 
disease are determinant factors in the decision to use CAM. 
Conclusion: The results of this work are relevant to health policy-makers and for insurance companies. Patients 
need freedom of choice and, for the sake of safety and efficacy of treatment, WM and CAM healthcare ought to be 
provided in a joint and integrated health system.
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Implications for policy makers
• Complementary/Alternative Medicine (CAM) and Western Medicine (WM) are complements, both in the diagnosis and treatment stages. 
• After a WH diagnosis, people may look for a CAM treatment.
• It is not socially desirable to separate WM from CAM in the NHS.
• Patient empowerment, education and individual characteristics are relevant for the choice of CAM.
Implications for public
Private health insurance providers may exploit the desire of people for access to both Complementary/Alternative Medicine (CAM) and Western 
Medicine (WM) and explore a niche of this market. Additional research on the relationship between income and the use of CAM is needed. The use 
of CAM is more frequent than it seems. 
Key Messages 
Background
The use of Complementary/Alternative Medicine (CAM) 
is becoming more and more common. A broad concept 
of CAM is used here including all modalities of medicine 
which are not considered conventional, or allopath, Western 
Medicine (WM). This approach is actually aligned with the 
definition proposed by World Health Organization (WHO) 
(1), which accordingly refers to a broad set of healthcare 
practices that are not part of that country’s own tradition 
and are not integrated into the dominant healthcare system. 
Examples of CAM in this work include: acupuncture, 
natural products, herbal care, homeopathy, osteopathy, 
phytotherapy and chiropractic care. The definition of 
CAM used here does not distinguish between the different 
therapeutic medical traditions; they are all given equal 
consideration as alternatives to allopath medicine. However, 
this definition is not very different from the one proposed 
by the European Information Centre for Complementary 
and Alternative Medicine (2). Accordingly, “the most 
commonly used CAM therapies in Europe are: homeopathy, 
phytotherapy, antroposophic medicine, naturopathy, traditional 
Chinese medicine, osteopathy and chiropractic”. Finally, these 
definitions are also very close to the definitions suggested by 
the CAMbrella project (3). This project views complementary 
and alternative medicine as a group of diverse medical and 
healthcare systems, practices, and products that are not 
generally considered part of conventional medicine.
Access to and use of CAM has been increasing in Europe 
since the mid-1980s (4,5). In general, the reasons people 
use CAM are various and can be summarized as follows: a 
need for self-empowerment regarding healthcare, a feeling of 
dissatisfaction with and distrust of  WM, and individual values 
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and beliefs (6,7). These reasons have been also identified for 
Portuguese users of CAM (8). 
The efficacy and safety of the use of CAM therapies are 
controversial. On the one hand, the benefits arising from 
the use of particular CAM therapies are recognized for some 
diseases such as cancer, asthma, diabetes, cardiovascular 
diseases, liver diseases and rheumatology (9–12). On the 
other hand, these benefits lack thorough scientific and 
clinical evidence (13–15). Moreover, undesirable interactions 
between CAM and WM treatments are well-known. For 
instance, the pharmacokinetic interactions between St. John’s 
wort and certain prescribed drugs (16) or between cat’s claw 
and specific blood medication (17) are well-documented. 
Several research papers review the interaction between herbs, 
homeopathic and allopathic drugs (18–21). The interactions 
between traditional Chinese medicines and western 
therapeutics have been reviewed recently (22).
While acknowledging both the reasons why people choose 
CAM and also the concern for patient safety and treatment 
efficacy, the following questions can be raised:
• Are CAM and WM substitutes or complements in the 
individual decision regarding healthcare?
• How is the relationship between CAM and WM different 
in the diagnosis and treatment stages?
• What are the main factors determining the individual 
choice of CAM?
Portugal has a strong tradition of conventional healthcare 
and so the National Health System does not include any 
CAM provision. The Portuguese public health system covers 
the whole population where care is mainly provided without 
significant copayments, except in the case of drugs [Further 
details of the Portuguese health system can be found in Barros 
and Simoes (23)].
Despite this wide coverage, some people choose to buy 
voluntary private health insurance; it is estimated that around 
20% of the population is covered by private voluntary health 
insurance (24)1.
The total cost of any CAM provision is borne by the 
individual. Moreover, because of the strong tradition of 
conventional healthcare, physicians know little about CAM 
and they do not approve it (25,26). This attitude helps to 
explain the ignorance people have of CAM and the fact that 
they do not actively request it. This backdrop means that 
Portugal provides a natural case study for the relationship 
between CAM and WM medicines. 
This work employs the forth Portuguese National Health 
Survey, published in 2006. The questions in this survey allow 
a distinction to be made both between the use of CAM and 
WM, and also between the diagnosis and the treatment, once 
some illness symptoms arise. 
Two probit models are estimated, reflecting the binary 
nature of the target and dependent variables showing 
whether or not CAM was used, while also allowing analysis 
of the explanatory variables underlying the behaviour of 
the dependent variables. The probit estimates provide the 
correlation between the use of CAM and WM. 
The theoretical basis for this analysis is the well-known 
model of demand for health proposed by Grossman (27). 
Accordingly, factors such as age, income and education 
are viewed as determinants of the demand for health. The 
applications of this work are several and they provide the 
empirical background for the independent variables used in 
the work presented here (28–31).
A relevant branch of the existing literature is related to the 
efficacy, safety, and also cost effectiveness of CAM (32,33). 
There is also some work on the use of CAM for particular 
diseases and on the attitude of physicians towards CAM 
(34,35). A systematic review of the literature for a selection of 
countries is carried out by Harris and Rees (5).
For the case of developing countries, Das and Choudhury 
(36) determine the socio-economic factors of CAM use 
and estimate the cost effectiveness of such choice in India. 
However, they do not study the correlation between the uses 
of CAM and WM. Van Gameren (37) analyzes the effect of 
insurance coverage on the use of CAM in Mexico. He finds 
that CAM is substituted by WM covered by insurance and 
that higher income households substitute less than lower 
income households.
The USA is the most studied of all the developed countries. 
Here, the work of Wolsko et al. (38) is worthy of note, where 
a study is made of the effect insurance coverage has on the 
frequency of CAM use, finding a positive correlation. Pagan 
and Pauly (6) try to understand if the reason people use 
CAM has more to do with saving money or their personal 
beliefs. Their results show that people who could not afford 
WM were more likely to use CAM. Tom Xu and Farrell (39) 
study the correlation between CAM and WM among racial 
and ethnic groups in the United States. Their results indicate 
that the complementarity and substitution of CAM and 
WM varies depending on the racial and ethnic group and by 
type of CAM. These are similar to the determinant factors 
explaining the use of CAM found by other researchers (40). 
Finally, an older study by Astin (7) looks for the different 
motives that led people to choose CAM in the USA, but no 
correlation is made with traditional medicine.
The literature on Europe has been increasing in last few years 
and concern with CAM in the health systems is flourishing. 
It is possible to find research work studying nearly every 
European country while a vast survey was undertaken by 
the CAMbrella project in 2009–12 (41,42). This project 
represented a step towards harmonizing existing knowledge 
and determining the knowledge gaps in this field. The results 
of the project yielded recommendations for the European 
Commission and the European Parliament.
European studies of the prevalence of CAM tend to be 
poor and heterogeneous (43) and also tend to display huge 
variability in the national regulatory management which 
makes a comparison across the EU nearly impossible (44). 
Some of the research published looks at the determinants of 
the use of CAM in countries like Finland (45), Italy (46,47), 
Germany (48), Sweden (49,50) and the UK (51). An overview 
of the results presented by this European research shows that 
there is a tendency to find common factors explaining the 
use of CAM; users are more likely to be women, middle aged, 
well-educated and from higher income brackets and suffering 
chronic conditions. Nevertheless, no work was found studying 
the relationship between CAM and WM in general, despite 
work having been done looking at the relationship for specific 
conditions such as cancer (52,53) and HIV (54).
Our work tries to fill a gap in the research regarding the 
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use of CAM in Southern European countries. Up until 
now, little work has been done: i) testing the relationship 
between CAM and WM, where the WM is mainly provided 
by a National Health System that does not include any CAM, 
and ii) estimating the determinants of CAM choice. iii) 
Moreover, as far as the author is aware, no research has been 
done differentiating CAM from WM in the diagnosis and 
treatment stages. 
The main result of this analysis is that for both cases of 
diagnosis and treatment CAM and WM are complementary 
choices for the individual. This result and the other results 
presented in this work provide a new and broader view 
concerning the use of CAM in Portugal. As a start point, 
health policy-makers should take into account the well-being 
and satisfaction of patients. Not only is this relevant from a 
safety and efficacy perspective, but also from a standpoint of 
freedom of choice by individuals. From a market perspective, 
private health insurance providers may see CAM as a niche to 
be explored.
Methods
Data and descriptive statistics
The data employed is taken from the forth Portuguese 
National Health Survey (2005/06) providing a representative 
sample for the country as a whole, since it results from a 
multi-stage random probability selection design. The survey 
includes a broad set of questions covering several topics 
from personal identification to sport and drinking habits. 
The responses received came from all people in the selected 
households who accepted to participate. Nationally, 76% of 
the selected households agreed to participate; reasons given 
for non-participation included “nobody resident at that 
address”, “incompatible schedules with interviewers” and 
“refusal” (the rate of refusal was only 5%). 
Trained interviewers asked the questions and recorded the 
answers during face-to-face interviews with a household 
representative or the individual himself. 
The working sample covers all 33,770 adults (older than 18), 
where 47.5% are males and 52.5% are females. There are two 
survey questions that relate to the use of CAM. One question 
asks about the diagnosis and the other about the treatment 
after a pre-reported illness or symptoms, as shown in Figure 
1. In answering the questions, respondents are obliged to 
choose one of three answers: “yes”, “no” or “do not know”. 
The number of “do not know” answers is insignificant. The 
relevant questions are presented in the Appendix 1.
A total of 855 people report using CAM, either in one or both 
the diagnosis and treatment stages. Table 1 shows the number 
of users of WM and CAM, according to their choices in the 
diagnosis and/or treatment stages. It should be noted that it is 
not possible to sum the numbers presented in Table 1 because 
there are some people who use CAM purely for diagnosis, 
other people who use CAM purely for treatment and other 
people again who use CAM for both diagnosis and treatment.
In order to refine the descriptive statistics on the use of CAM 
and because information on the use of CAM is preceded by 
information recording a feeling of being ill in the two weeks 
prior to the survey, we now present some additional statistics 
on the use of CAM. The supporting structure of the described 
statistics is presented in Figure 2.
The number of adults reporting “feeling ill” in the two weeks 
prior to the survey was 5,070. Table 2 shows that out of this 
group of 5,070 people, 2,056 looked for a WM professional 
to get a diagnosis and 68 looked for a CAM diagnosis, while 
379 people used a treatment provided by CAM. The total 
number of people reporting using CAM and feeling ill is 408. 
As before, in Table 2, the sum of the entries does not yield the 
total users of CAM because people use CAM in one or both 
stages of healthcare. 
For those people that sought a WM diagnosis (that is 2,056 
people), Table 3 shows the subsequent choice breakdown 
concerning treatment. Only 649 people followed up from 
their diagnosis with some form of treatment. From this group, 
487 people (23.7%) took a WM treatment (usually drugs), 
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Question about feeling 
ill 
Question about diagnosis 
for symptoms or illness 
Question about treatment for 
symptoms or illness 
Dependant variable 
CAM diagnosis 
Dependant variable 
CAM treatment 
Figure 1. Flowchart for the questions concerning Complementary/
Alternative Medicine (CAM) in the survey
Figure 2. Supporting structure of the additional descriptive statistics
Table 1. Number of users of WM and CAM
 WM CAM
Diagnosis 4,258 124
Treatment 2,598 810
CAM= Complementary/Alternative Medicine; WM= Western Medicine
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Figure 2. Supporting structure of the additional descriptive statistics 
 
 
 
 
 
  
People feeling ill: 5,070 
Treatment 
People 
reporting 
use of WM: 
5,940 
People 
reporting use 
of CAM: 855 Diagnosis 
Table 2. Number of users by type of medicine for people reporting “felling 
ill”a
WM CAM
 No. of users % No. of users %
Diagnosis 2,056 40.6 68 1.3
Treatment 1,710 33.7 379 7.5
CAM= Complementary/Alternative Medicine; WM= Western Medicine.
a The percentage refers to total numbers of people feeling ill = 5,070.
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while 162 (7.9%) people decided upon a CAM treatment after 
the WM diagnosis. These are unexpected numbers because of 
the divergence in choices between the type of diagnosis and 
treatment undertaken.
The three most common types of CAM specialist sought for 
a diagnosis are phytotherapists (27%), herbal experts (24%) 
and acupuncturists (15%). This pattern of CAM use changes 
when it comes to treatment, where the three most sought 
after forms of treatment are herbs and teas (44%), “other” 
(33%) and chiropractic (19%). No information is available 
to determine what “other” means, but it can be inferred to 
include all other CAM which are not on the list of possible 
choices in the survey, such as, yoga, reiki, cripto therapy 
and massage.
To uncover more information about the relationships at play, 
an analysis is made of the correlation between the choices 
of CAM and WM for treatment and diagnosis (CAMdiagn, 
CAMtreat, WMdiagn and WMtreat – these variables are 
binary taking on a value of 1 if the individual reported uses 
CAM and 0 otherwise). In the next table, the tetrachoric 
correlations (The tetrachoric correlation is a coefficient 
computed for two normally distributed binary variables) are 
shown for the four variables, as well as Cramer’s V statistic 
measuring the association between two binary variables 
(in brackets).
The values in Table 4 show that the choices of CAM and WM 
for diagnosis and treatment exhibit in all cases a strong or 
medium positive correlation. Moreover, they are not strongly 
associated, that is, each pair of two variables are far from being 
equal to each other since Cramer’s V statistic is very low.
The survey questions supporting the variables relating to the 
choice of CAM or WM are presented in Appendix 1, along 
with information on how the variables were created.
Method and model
The relationship between CAM and WM may be either 
complement or substitute. These concepts are borrowed 
Table 3. Number of users by type of treatment for people reporting being 
ill and doing WM diagnosisa
 No. of users %
WM treatment 487 23.7
CAM treatment 162 7.9
CAM= Complementary/Alternative Medicine; WM= Western Medicine.
a Percentage refers to total numbers= 2,056.
Table 4. Correlations and associationsa
 CAMdiagn CAMtreat WMdiagn WMtreat
CAMdiagn 1 - - -
CAMtreat 0.937
(-0.236)
1 - - 
 
WMdiagn 0.694
(-0.073)
0.729
(-0.211)
1 - 
 
WMtreat 0.588
(-0.056)
0.439
(-0.076)
0.533
(-0.196)
1
 
a In brackets the Cramer’s V statistic.
Table 5. Independent variables
Variable Description
Variables describing social and economic status
Gender 1 if male; 0 if female
Age Number of years of age
Age2 Square of Age
Income Income per capitaa
Variables describing personal status
Single 1 if single; 0 otherwise
Married 1 if married; 0 otherwise
Divorced 1 if divorced; 0 otherwise
Alone 1 if alone; 0 otherwise
Set of variables describing personal occupation
Work 1 if works; 0 otherwise
Student 1 if studies; 0 otherwise
Unemploy 1 if unemployed; 0 otherwise
Retired 1 if retired; 0 otherwise
Variables describing health status
Chrndis
1 if individual has at least one chronic diseaseb; 0 
otherwise
BMI Body Mass Indexc
Variables describing education and empowerment
Schyr School years: number of completed schooling years
Schyr2 Square of Schyr
Selfmed
1 if individual chose to take drugs without 
conventional doctor prescription; 0 otherwise
a Income is computed from the average income of an interval of incomes 
chosen by respondent, divided by the square of the number of individuals 
in the family in order to take into account economies of scale.
b The chronic diseases considered are the following: diabetes, asthma, 
high blood pressure, chronic pain, rheumatism, osteoporosis, glaucoma, 
retina diseases, cancer, kidney diseases, anxiety, chronic wound, 
bronchitis, Cerebrovascular Accident (CVA), obesity, depression and heart 
attack.
c BMI is computed as a ratio between the weight in kilograms and the 
square of the height in meters.
from the economic theory, in the sense that when the 
consumption of CAM and WM increases, then they tend 
to be complementary, but when the consumption of CAM 
decreases and the WM increases, then they are substitutes. 
To find the relationship between CAM and WM, two linear 
equations are estimated, based on several control variables. 
This econometric approach to test the complementarity of 
goods and services in health has been used before (55–58).
The dependent variables of the econometric model are 
CAMtreat and CAMdiagn. These are binary variables, 
taking a value of 1 if the individual reported using CAM 
and 0 otherwise. The aim to estimate the main determinants 
of a CAM decision justifies the choice of CAM as a 
dependent variable.
The independent variables are listed and described in Table 5.
For the diagnosis scenario, the estimated probit is as follows:
CAMdiagn = c1 + α1 X + δ1 WMdiagn + v1, 
While for the treatment scenario we have:
CAMtreat = c2 + α2 X + δ2 WMtreat + δ3 CAMdiagn +δ4 
WMdiagn + v2
where X are independent variables, ci is a constant, and vi is 
the error term, i = 1,2. 
According to the definition of complementarity and 
substitutability, if the estimated δ’s are positive, then CAM 
and WM are complements; if negative, then CAM and WM 
are substitutes.
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Another relevant economic estimate concerns the correlation 
between income and the choice of CAM. If the estimated 
coefficient is positive, then CAM is a normal good, however, 
if it is negative, then it is an inferior good.
Finally, the estimated coefficients for the control variables 
provide information about the correlation each variable has 
with the choice of CAM, given that all the other variables 
are constant.
Results
The estimated models are presented in the next table and 
were obtained with software STATA version 9 (Table 6).
The most relevant result is that CAM and WM are 
complements, both in the diagnosis and treatment stages, 
because estimated coefficients are positive and statistical 
significant.
The second important result is that people, having sought a 
WM diagnosis, may look for a CAM treatment, as shown in 
estimated coefficients of model 1. This result actually shows 
how CAM and WM are related for patients who seem to value 
both healthcare contributions. This corroborates previous 
medical studies that showed the importance of CAM in 
particular diseases.
Table 6. Results of the estimated modelsa
CAM treatment
Model 1
CAM diagnosis
Model 2
Coef. P>|z| Coef. P>|z|
WMtreat 0.150 0.015 - -
CAMdiagn 1.944 0.000 - -
WMdiagn 0.955 0.000 0.779 0.000
Gender -0.049 0.239 -0.063 0.419
Income 0.000 0.992 0.000 0.830
Age 0.019 0.013 0.043 0.005
Age2 0.000 0.027 0.000 0.017
Schyr 0.044 0.073 0.058 0.149
Schyr2 -0.003 0.047 -0.002 0.341
Single -0.119 0.229 -0.112 0.491
Married -0.176 0.036 -0.233 0.084
Widow -0.125 0.240 -0.349 0.081
Work -0.165 0.002 -0.027 0.784
Unemploy -0.148 0.129 -0.015 0.938
Retired 0.009 0.894 0.006 0.965
Smoke 0.136 0.005 -0.189 0.061
Chrndis 0.225 0.000 0.226 0.013
BMI 0.001 0.864 -0.002 0.753
Selfmed 0.278 0.000 0.644 0.000
Cons -2.916 0.000 -4.236 0.000
Number of observation 27,131 27,131
Wald chi2 1207.680 283.740
Prob> chi2 0.000 0.000
Log pseudolikelihood -2422.211 -614.351
Pseudo R2 0.202 0.161
BMI= Body mass index
a The non-significant coefficients in regular font; significant coefficients in 
bold.
The third result worth stressing is that the medical 
literacy and empowerment of patients, captured by the self-
medication variable, contributes towards choosing CAM. 
Moreover, this medical literacy and empowerment can also 
be captured by the existence of chronic disease. These patients 
tend to understand their condition well, along with what 
makes them feel better, and they are usually willing to try new 
approaches to their illness. This is why suffering from at least 
one chronic disease is a determinant factor in choosing CAM.
The other result concerning literacy comes from the 
significance education holds for the choice of CAM 
treatment, but not for the CAM diagnosis. The higher the 
level of education, the more likely it becomes for individuals 
to choose a CAM treatment. However, the marginal effect 
on individuals’ choice as education increases is negative; 
education presents an inverted U-shape relationship with 
CAM treatment.
A somewhat surprising result is that smokers are less likely 
to look for a CAM diagnosis than a CAM treatment. The 
descriptive statistics show that 810 smokers use CAM 
treatments while only 124 smokers use a CAM diagnosis. 
It is not possible to identify the reasons that encouraged 
smokers to look for CAM. However, it follows that smoking 
as a condition does not need a diagnosis, and those wishing 
to follow programs designed to quit smoking are looking for a 
CAM treatment and not a diagnosis.
Finally, no significant relationship was found between the 
choice of CAM and income, leaving us unable to reach a 
conclusion as to whether CAM represents a normal or inferior 
good for consumers.
These results obtained here are relevant for health policy 
matters. Firstly, it may be important for the well-being of 
patients to have a national health system that integrates both 
types of medicines. This could help increase the clarity and 
availability of information for physicians and for patients, 
and increase communication between them, so that higher 
efficacy and safety, as well as, access equity could be achieved.
Secondly, it may be inferred that there exists an increasing 
interest in including CAM in private health insurance. While 
this practice is already current in other European countries, 
it is now becoming more common in Portugal due to the 
positive correlation between CAM and WM medicines.
Thirdly, the characterization of those who choose CAM 
is helpful for policy design. People suffering from chronic 
diseases, smokers, working and mature adults are those who 
are more likely to appreciate such health policies.
Finally, it could be argued that the estimation of these two 
probit models could be done simultaneously, in order to 
account for possible endogeneity. A bivariate probit was 
estimated where upon the results were found to be identical to 
the original estimation. Moreover, no significant correlation 
was found between the residuals of both probits regressions, 
which most likely means there is no endogeneity. This can 
be explained by the strong belief and cultural bias towards 
conventional medicine in Portugal.
Conclusions and Discussion
The increasing use of CAM by the Portuguese follows the 
European trend. The questions raised by this trend are 
several: Are CAM and WM substitutes or complements in 
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the individual decision regarding healthcare? How is the 
relationship between CAM and WM different in the diagnosis 
and treatment stages? What are the main factors determining 
the individual choice of CAM?
The interaction between prescribed WM drugs and CAM 
therapies is well-known. The importance of this coupled 
with a concern for the patient’s safety, satisfaction and the 
treatment efficacy, justifies this work.
In this work data is used from the forth Portuguese National 
Health Survey (2005/06) where two probit models are 
estimated for CAM diagnosis and treatment. It is found that 
CAM and WM are complements, both in the diagnosis and 
treatment stages.
This main result, along with the relevance of patient 
empowerment and individual patient characteristics, 
provides important insights for health policy-makers and for 
private health insurance providers.
The determinant factors of the use of CAM found in this 
work are not very different from those found in other 
research work. Some differences arise, as for instance with 
gender, which is not a significant factor in the current work 
in contrast with other studies (46–48). Even if no explanation 
may be provided for this, it is expected that as soon as the 
prejudice surrounding open discussion of CAM diminishes, 
gender may be a significant determinant factor driving the 
choice of CAM.
Income is similarly poor at explaining CAM use. While 
in other European research (47,48,51), income has had a 
significant capacity to explain CAM prevalence, here that 
does not appear to be the case. The reason for this may be due 
to the way the variable is defined (in classes), meaning it does 
not capture much of the variability in the use of CAM.
The last difference worth mentioning relates to education. 
The results found for schooling are inconclusive since the 
estimated coefficient was significant for CAM treatment 
but not for CAM diagnosis. This provides a basis for future 
research as other studies (46–48,51) found a significant 
relationship and this work finds a negative marginal effect 
of education on the choice of CAM. This may be interpreted 
as a decreasing effect of education for very high levels of 
education.
The results obtained in this work seem to show that the 
separation between WM and CAM is not socially desirable. 
Patients need for freedom of choice and, for the sake of safety 
and efficacy of treatment, WM and CAM healthcare should 
be provided in a joint and integrated health system.
From a different perspective, private health insurance 
providers may exploit the desire of people for access to 
both WM and CAM and explore a niche of this market. 
In particular, advertising such health insurance to mature 
working adults who tend to smoke more often.
The main disadvantage of this analysis is the number of 
people self-reporting using CAM. This number may be 
smaller than the true number of people using CAM diagnosis 
and treatment. This under-reporting can be explained by the 
fact that Portuguese society is WM dominated and CAM 
is little known or understood, leading people to not openly 
discuss its use. Hence, one potential limitation arises from the 
fact that it is not possible to interpret what is the meaning of 
negative answers to the survey questions used to create the 
observable variables on use of CAM. Does it mean “no use of 
CAM”? Or does it mean “I do not want to talk about it”? 
Lastly, the economic quantitative analysis and the database 
used in this work does not allow for a qualitative analysis 
where cultural, social and anthropological features also 
play a role. The emphasis of the work presented here has 
quantitative nature. 
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Endnotes
This work was done before the full effects of the debt crisis took hold in 2011. 
At that time, the National Health Service (NHS) copayments were fairly low. 
In 2010, it was estimated that on average about 30% of total expenditure on 
healthcare was private, mainly in the form of out-of-pocket (OOP) payments. 
After 2011, some reforms have been implemented in order to decrease public 
expenditure on health (25). However, an assessment of these measures has 
not been made. Moreover, due to financial constraints, there is no statistical 
information about the current use of CAM nor is there any health survey.
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Appendix 1 
I) Question for Diagnosis Stage
“Related to that (health) problem you mentioned before, to whom 
did you go?”
1) Doctor
2) Nurse
3) Pharmacist
4) Acupuncturist
5) Homeopaths
6) Osteopaths
7) Naturopaths
8) Phytotheraphist
9) Chiropractor
10) Herbal expert
11) Healer
12) Other health professional
Variable CAMdiagn is created by at least one answer being chosen 
from options 4 to 10.
Variable WMdiagn is created by at least one answer being chosen 
from options1 to 3.
II) Question for Treatment Stage
“In relation to the (health) problem you mentioned before, what 
treatment have you administered in the last two weeks?”
1) Herbs and teas
2) Change of food
3) Took drugs you knew
4) Took drugs advised by friends
5) Took drugs advised by doctor
6) Acupuncture
7) Homeopathy
8) Osteopathy
9) Naturapathy
10) Phytotherapy
11) Chiropractic
12) Something else
Variable CAMtreat is created by at least one answer being chosen 
out of theoptions1 and 6 to 11.
Variable WMtreat is created by at least one answer being chosen 
from options 3 to 5.
